Rhythm Pharmaceuticals (RYTM) – Investment Analysts’ Recent Ratings Changes

A number of firms have modified their ratings and price targets on shares of Rhythm Pharmaceuticals (NASDAQ: RYTM) recently:

• 10/16/2026 – Rhythm Pharmaceuticals is now covered by William Blair. They set an “outperform” rating on the stock.
• 10/15/2026 – Rhythm Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/15/2026 – Rhythm Pharmaceuticals had its price target lowered by JPMorgan Chase & Co. from $146.00 to $145.00. They now have an “overweight” rating on the stock.
• 10/12/2026 – Rhythm Pharmaceuticals had its price target raised by HC Wainwright from $105.00 to $130.00. They now have a “buy” rating on the stock.
• 10/8/2026 – Rhythm Pharmaceuticals had its price target raised by Royal Bank Of Canada from $155.00 to $159.00. They now have an “outperform” rating on the stock.
• 9/17/2026 – Rhythm Pharmaceuticals is now covered by Wolfe Research. They set an “outperform” rating on the stock.
• 9/14/2026 – Rhythm Pharmaceuticals is now covered by Leerink Partners. They set an “outperform” rating and a $133.00 price target on the stock.
• 8/28/2026 – Rhythm Pharmaceuticals is now covered by Deutsche Bank Aktiengesellschaft. They set a “hold” rating and a $120.00 price target on the stock.

Insider Buying and Selling

In other Rhythm Pharmaceuticals news, insider Alastair Garfield sold 7,763 shares of the company’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $117.57, for a total transaction of $912,695.91. Following the completion of the sale, the insider owned 2,295 shares in the company, valued at $269,823.15. This represents a 77.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jennifer Lee sold 75,834 shares of the company’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $117.38, for a total value of $8,901,394.92. Following the sale, the executive vice president owned 54,233 shares of the company’s stock, valued at approximately $6,365,869.54. This represents a 58.30% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 258,450 shares of company stock valued at $28,796,497 over the last ninety days. Company insiders own 5.90% of the company’s stock.

Rhythm Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare genetic diseases of obesity and related metabolic disorders. The company’s work is based on the melanocortin-4 receptor (MC4R) pathway, which plays an important role in regulating hunger and energy balance.

Rhythm’s principal product is IMCIVREE (setmelanotide), a targeted therapy designed to restore impaired MC4R pathway signaling. In the United States, IMCIVREE is approved for chronic weight management in adults and children at least 6 years old with obesity caused by certain genetic deficiencies, including POMC, PCSK1, or LEPR deficiency, as well as Bardet-Biedl syndrome.